StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on SpyGlass Pharma (SGP)

Wed, 21 Oct 2026 06:49:21 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $37.00 price target on SpyGlass Pharma (NASDAQ: SGP).

The analyst commented: "Four-year data support sustained IOP control with 86% of patients remaining off drops. Earlier this week, SpyGlass Pharma reported positive four-year data from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL) in patients with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. Among 21 evaluable patients across three dose groups, mean intraocular pressure (IOP) declined 37% from 25.1 mmHg at baseline after medication washout to 15.9 mmHg. In addition, 18 patients (86%) remained off all topical

Form 8-K SpyGlass Pharma, Inc. For: Oct 19

Mon, 19 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261019/27203966.html

SpyGlass Pharma reports 4-year glaucoma implant trial data

Mon, 19 Oct 2026 08:04:38 -0400

SpyGlass Pharma, Inc. (Nasdaq: SGP) announced interim 4-year results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), a sustained drug delivery implant designed for patients with mild-to-moderate open angle glaucoma or ocular hypertension undergoing cataract surgery.

Data from 21 evaluable patients showed a 37% reduction in mean intraocular pressure (IOP), falling from 25.1 ± 2.5 mmHg at baseline to 15.9 ± 2.8 mmHg. In addition, 86% of patients remained off all topical IOP-lowering drops, and 90% maintained best corrected distance visual acuity of 20/25 or better. No product-related adverse events were reported.

The trial originally enrolled 23 patients

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Mon, 19 Oct 2026 08:00:00 -0400

Groundbreaking 4-year safety and efficacy results:

37% reduction in mean intraocular pressure (IOP) across all dose groups
86% of patients remained off all topical IOP-lowering drops
90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA)
No product-related adverse events were reported

IRVINE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines, today announced positive 4-year first-in-human (FIH) trial results

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Mon, 19 Oct 2026 08:00:00 -0400

Groundbreaking 4-year safety and efficacy results:

37% reduction in mean intraocular pressure (IOP) across all dose groups
86% of patients remained off all topical IOP-lowering drops
90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA)
No product-related adverse events were reported

H.C. Wainwright Reiterates Buy Rating on SpyGlass Pharma (SGP)

Mon, 05 Oct 2026 06:44:24 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $37.00 price target on SpyGlass Pharma (NASDAQ: SGP).

The analyst commented: "Last week, SpyGlass Pharma announced the acquisition of all outstanding common stock of Advanced Vision Science, Inc. (AVS) for approximately $13M in cash. AVS is a manufacturer of intraocular lenses (IOLs) and lens materials, and it is the current supplier of SpyGlass’ IOL in its two Phase 3 registrational trials of the BIM-IOL System. AVS was a subsidiary of Santen Pharmaceutical Co., Ltd (4536.T; not rated). Under the agreement, AVS will be the exclusive manufacturer and supplier of several types

SpyGlass Pharma (SGP) Reiterated at Buy by Stifel as AVS Acquisition Announced

Fri, 02 Oct 2026 08:03:47 -0400

Stifel analyst Tom Stephan reiterated a Buy rating and $42.00 price target on SpyGlass Pharma (NASDAQ: SGP).

The analyst commented, "Earlier this morning, SGP announced the acquisition of Advanced Vision Science (AVS), a subsidiary of Santen Pharmaceutical and the existing third-party manufacturer of SGP's IOL, for approximately $13M in cash. AVS is the current supplier of SGP's IOL for both of its ph3 registrational trials of the BIM-IOL System, and the deal importantly secures scalable commercial manufacturing capacity. Under the agreement, AVS will remain the exclusive IOL manufacturer/supplier to Santen for Japan commercialization and will continue licensing its glistening-free hydrophobic acrylic

Form 8-K SpyGlass Pharma, Inc. For: Oct 01

Thu, 01 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261001/27131993.html

SpyGlass Pharma buys AVS from Santen for $13 million

Thu, 01 Oct 2026 08:02:30 -0400

SpyGlass Pharma, Inc. (Nasdaq: SGP) announced the acquisition of Advanced Vision Science, Inc. (AVS), a California-based intraocular lens (IOL) manufacturer, from Santen Pharmaceutical Co., Ltd. for approximately $13 million in cash.

AVS, which has been manufacturing ophthalmic devices since 1975, is the current supplier of SpyGlass Pharma's IOL used in two Phase 3 clinical trials evaluating its Bimatoprost Drug Pad-IOL System (BIM-IOL System), a drug delivery device designed to be implanted during cataract surgery to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Under the terms of the agreement, AVS will serve as the exclusive manufacturer and supplier

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

Thu, 01 Oct 2026 08:00:00 -0400

SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)
Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL System
Accelerates pathway to adding premium lens options into its IOL-based drug delivery system
SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies

IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

Thu, 01 Oct 2026 08:00:00 -0400

SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)
Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL System
Accelerates pathway to adding premium lens options into its IOL-based drug delivery system
SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies

IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or

Raymond James Starts SpyGlass Pharma (SGP) at Outperform

Fri, 14 Aug 2026 06:06:35 -0400

(Updated - August 14, 2026 6:06 AM EDT)

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.

The analyst comments "We are initiating coverage of SGP shares with an Outperform rating and $39 price target. At the center of our thesis is BIM-IOL, a proprietary sustained-release (SR) bimatoprost intraocular lens (IOL) designed to treat patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) at the time of routine cataract surgery. SGP is targeting the large overlap between cataract and glaucoma patients at a natural point of intervention, with a

Raymond James Starts SpyGlass Pharma (SGP) at Outperform

Fri, 14 Aug 2026 06:06:35 -0400

(Updated - August 14, 2026 6:06 AM EDT)

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.

Raymond James Starts SpyGlass Pharma (SGP) at Outperform

Fri, 14 Aug 2026 06:06:35 -0400

(Updated - August 14, 2026 6:06 AM EDT)

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.

Raymond James Starts SpyGlass Pharma (SGP) at Outperform

Fri, 14 Aug 2026 06:06:35 -0400

(Updated - August 14, 2026 6:06 AM EDT)

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.

SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59

Fri, 07 Aug 2026 16:15:16 -0400

SpyGlass Pharma (NASDAQ: SGP) reported Q2 EPS of ($0.59).

For earnings history and earnings-related data on SpyGlass Pharma (SGP) click here.

Form 10-Q SpyGlass Pharma, Inc. For: Jun 30

Thu, 06 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260806/26884930.html

Form 10-Q SpyGlass Pharma, Inc. For: Jun 30

Thu, 06 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260806/26884930.html

Form 8-K SpyGlass Pharma, Inc. For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884284.html

Form 8-K SpyGlass Pharma, Inc. For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884284.html

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates